EUVIMEDEUVIMED entdecken
Open Access

In Vivo Pharmacokinetic and Pharmacodynamic Properties of the Antiarrhythmic Molecule ent-Verticilide

Daniel J Blackwell, Abigail N Smith, Tri Do, Aaron Gochman, Jeffrey Schmeckpeper, Corey R Hopkins, Wendell S Akers, Jeffrey N Johnston, Bjorn C Knollmann iD

The Journal of Pharmacology and Experimental Therapeutics · 2023-06 · 385 (3) · 205-213

DOI: 10.1124/jpet.122.001455 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2023-06. Verfasst von Daniel J Blackwell und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (D.J.B., J.S., B.C.K.); Departments of Chemistry (A.N.S., J.N.J.) …. Hauptthemen laut MEDLINE: Ryanodine Receptor Calcium Release Channel, Tachycardia, Ventricular. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The unnatural verticilide enantiomer (ent-verticilide) is a selective and potent inhibitor of cardiac ryanodine receptor (RyR2) calcium release channels and exhibits antiarrhythmic activity in a murine model of catecholaminergic polymorphic ventricular tachycardia (CPVT). To determine verticilide's pharmacokinetic and pharmacodynamic properties in vivo, we developed a bioassay to measure nat- and ent-verticilide in murine plasma and correlated plasma concentrations with antiarrhythmic efficacy in a mouse model of CPVT. nat-Verticilide rapidly degraded in plasma in vitro, showing >95% degradation within 5 minutes, whereas ent-verticilide showed

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ryanodine Receptor Calcium Release ChannelTachycardia, VentricularMiceAnimalsAnti-Arrhythmia AgentsArrhythmias, CardiacMyocytes, CardiacDepsipeptides

Substanzen

Ryanodine Receptor Calcium Release ChannelAnti-Arrhythmia AgentsverticilideDepsipeptides

Autor:innen und Institutionen

  • Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (D.J.B., J.S., B.C.K.); Departments of Chemistry (A.N.S., J.N.J.) and Pharmacology (A.G., W.S.A), and Vanderbilt Institute of Chemical B…

ORCID-Profile: Bjorn C Knollmann

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Blackwell, D. J., Smith, A. N., Do, T., Gochman, A., Schmeckpeper, J., Hopkins, C. R., Akers, W. S., Johnston, J. N., & Knollmann, B. C. (2023). In Vivo Pharmacokinetic and Pharmacodynamic Properties of the Antiarrhythmic Molecule ent-Verticilide. The Journal of Pharmacology and Experimental Therapeutics, 385(3), 205-213. https://doi.org/10.1124/jpet.122.001455

Vancouver

Blackwell DJ, Smith AN, Do T, Gochman A, Schmeckpeper J, Hopkins CR, et al. In Vivo Pharmacokinetic and Pharmacodynamic Properties of the Antiarrhythmic Molecule ent-Verticilide. The Journal of Pharmacology and Experimental Therapeutics. 2023;385(3):205-213. doi:10.1124/jpet.122.001455

BibTeX
@article{Blackwell2023,
  author = {Blackwell, Daniel J and Smith, Abigail N and Do, Tri and Gochman, Aaron and Schmeckpeper, Jeffrey and Hopkins, Corey R and Akers, Wendell S and Johnston, Jeffrey N and Knollmann, Bjorn C},
  title = {In Vivo Pharmacokinetic and Pharmacodynamic Properties of the Antiarrhythmic Molecule ent-Verticilide},
  journal = {The Journal of Pharmacology and Experimental Therapeutics},
  year = {2023},
  volume = {385},
  number = {3},
  pages = {205--213},
  doi = {10.1124/jpet.122.001455}
}
Kostenlos starten →